logo
ABB Ltd Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

ABB Ltd Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next

Yahoo19-04-2025

It's been a good week for ABB Ltd (VTX:ABBN) shareholders, because the company has just released its latest first-quarter results, and the shares gained 4.8% to CHF42.20. It looks to have been a decent result overall - while revenue fell marginally short of analyst estimates at US$7.9b, statutory earnings beat expectations by a notable 18%, coming in at US$0.60 per share. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
Taking into account the latest results, the current consensus from ABB's 24 analysts is for revenues of US$34.6b in 2025. This would reflect a modest 5.0% increase on its revenue over the past 12 months. Per-share earnings are expected to rise 6.3% to US$2.40. In the lead-up to this report, the analysts had been modelling revenues of US$34.4b and earnings per share (EPS) of US$2.38 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
See our latest analysis for ABB
The analysts reconfirmed their price target of CHF47.03, showing that the business is executing well and in line with expectations. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. The most optimistic ABB analyst has a price target of CHF59.30 per share, while the most pessimistic values it at CHF34.02. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's clear from the latest estimates that ABB's rate of growth is expected to accelerate meaningfully, with the forecast 6.8% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 5.0% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 4.9% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that ABB is expected to grow much faster than its industry.
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.
With that in mind, we wouldn't be too quick to come to a conclusion on ABB. Long-term earnings power is much more important than next year's profits. We have forecasts for ABB going out to 2027, and you can see them free on our platform here.
You can also view our analysis of ABB's balance sheet, and whether we think ABB is carrying too much debt, for free on our platform here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AMD price target lift, Apple's WWDC, Chewy downgrade
AMD price target lift, Apple's WWDC, Chewy downgrade

Yahoo

time18 minutes ago

  • Yahoo

AMD price target lift, Apple's WWDC, Chewy downgrade

Market Domination co-host Josh Lipton tracks today's top moving stocks and biggest market stories in this Market Minute. Advanced Micro Devices (AMD) stock gains after Citi lifts its price target to $120 from $100, citing upcoming artificial intelligence (AI) catalysts and advantages over Nvidia (NVDA). Apple (AAPL) is kicking off its Worldwide Developers Conference on Monday, where the company is expected to unveil key software updates. Chewy (CHWY) stock slides after Mizuho downgraded the stock to Neutral from Outperform. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute. It's time for Yahoo Finance's market minute. US stocks seesaw as investors eye renewed US-China trade talks. Wall Street looking for signs of either side willing to dial down tensions and reach a tariff deal. AMD shares getting a lift as City raises its price target on that stock from 100 to 120. City highlighting potential positive catalyst, the second half of the year and sees the chip maker as having some advantages over Nvidia. The price target change comes ahead of AMD's advancing AI event, which is taking place on June 12th. Apple kicking off its worldwide developers conference on Monday. The iPhone maker offering a look at the changes coming to the company's software products throughout the next year. Apple expected to reveal software and design updates. And Chewy shares, they're sliding as Mizuho hits the stock with a downgrade, lowering its rating from outperform to neutral. Mizuho citing the pet food company's unattractive positioning, noting quote, several potential landmines for the first quarter. And that's your Yahoo Finance market minute. Sign in to access your portfolio

June 2025's Spotlight On Promising Penny Stocks
June 2025's Spotlight On Promising Penny Stocks

Yahoo

time37 minutes ago

  • Yahoo

June 2025's Spotlight On Promising Penny Stocks

As the U.S. stock market experiences a rally fueled by optimism over U.S.-China trade talks and robust corporate earnings, investors are increasingly exploring diverse investment opportunities. Penny stocks, a term that may seem outdated yet remains relevant, represent shares of smaller or newer companies that can offer significant growth potential when backed by strong financial health. In this article, we will explore several penny stocks that demonstrate balance sheet strength and long-term potential, providing investors with opportunities to uncover hidden value in the market. Name Share Price Market Cap Financial Health Rating Imperial Petroleum (IMPP) $3.02 $103.93M ★★★★★★ New Horizon Aircraft (HOVR) $0.935 $29.35M ★★★★★★ Waterdrop (WDH) $1.475 $533.45M ★★★★★★ Greenland Technologies Holding (GTEC) $2.06 $35.83M ★★★★★★ WM Technology (MAPS) $1.11 $186.68M ★★★★★★ Perfect (PERF) $1.815 $184.86M ★★★★★★ Table Trac (TBTC) $4.86 $22.55M ★★★★★★ Flexible Solutions International (FSI) $4.32 $54.64M ★★★★★★ BAB (BABB) $0.8311 $6.04M ★★★★★★ Lifetime Brands (LCUT) $3.43 $76.88M ★★★★★☆ Click here to see the full list of 709 stocks from our US Penny Stocks screener. Let's review some notable picks from our screened stocks. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated and metabolic diseases, with a market cap of approximately $159.32 million. Operations: Aldeyra Therapeutics, Inc. does not report any revenue segments. Market Cap: $159.32M Aldeyra Therapeutics, with a market cap of US$159.32 million, is a pre-revenue biotechnology firm navigating the challenging landscape of clinical trials and regulatory approvals. Despite recent setbacks from the FDA regarding its dry eye treatment candidate reproxalap, the company achieved significant milestones in Phase 3 trials that may address previous concerns. Financially, Aldeyra maintains strong short-term liquidity with US$92.7 million in assets against liabilities and has more cash than debt, providing a runway exceeding one year. However, high volatility and ongoing losses highlight inherent risks typical for companies at this developmental stage in the biotech sector. Unlock comprehensive insights into our analysis of Aldeyra Therapeutics stock in this financial health report. Explore Aldeyra Therapeutics' analyst forecasts in our growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Maravai LifeSciences Holdings, Inc. is a life sciences company that offers products supporting the development of drug therapies, vaccines, cell and gene therapies, and diagnostics across various global regions with a market cap of $608.64 million. Operations: The company generates revenue primarily from Nucleic Acid Production, which accounts for $179.08 million, and Biologics Safety Testing, contributing $62.78 million. Market Cap: $608.64M Maravai LifeSciences Holdings, with a market cap of US$608.64 million, faces challenges typical for penny stocks, including recent declines in sales and increased net losses. The company reported first-quarter sales of US$46.85 million, down from US$64.18 million a year prior, and a net loss of US$29.95 million compared to the previous year's US$12.08 million loss. Despite its unprofitability, Maravai has strong short-term liquidity with assets surpassing both short- and long-term liabilities and has reduced its debt-to-equity ratio over five years from 262.7% to 55.6%, indicating improved financial management amidst volatility concerns. Navigate through the intricacies of Maravai LifeSciences Holdings with our comprehensive balance sheet health report here. Assess Maravai LifeSciences Holdings' future earnings estimates with our detailed growth reports. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Ranpak Holdings Corp. offers product protection and end-of-line automation solutions for e-commerce and industrial supply chains across North America, Europe, and Asia, with a market cap of approximately $306.61 million. Operations: The company generates $374.8 million in revenue from its product protection and automation solutions for e-commerce and industrial supply chains. Market Cap: $306.61M Ranpak Holdings, with a market cap of US$306.61 million, exemplifies the volatility and potential of penny stocks. Despite being unprofitable with increasing losses over five years and a negative return on equity, Ranpak maintains a seasoned management team and board. The company reported first-quarter revenue growth to US$91.2 million but also faced a net loss of US$10.9 million. Recent strategic partnerships, like the one with Thalia for automated packaging systems, highlight its commitment to innovation in e-commerce fulfillment solutions while managing high debt levels and maintaining sufficient cash runway for over three years. Click to explore a detailed breakdown of our findings in Ranpak Holdings' financial health report. Understand Ranpak Holdings' earnings outlook by examining our growth report. Explore the 709 names from our US Penny Stocks screener here. Ready To Venture Into Other Investment Styles? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ALDX MRVI and PACK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Mitsubishi plans battery swapping tech for electric CVs in Tokyo
Mitsubishi plans battery swapping tech for electric CVs in Tokyo

Yahoo

timean hour ago

  • Yahoo

Mitsubishi plans battery swapping tech for electric CVs in Tokyo

Mitsubishi Fuso Truck and Bus (MFTBC), in collaboration with Mitsubishi Motors, Ample, and Yamato Transport, is set to roll out an EV battery swapping initiative in Tokyo, Japan, by September 2025. The plan includes introducing more than 150 battery-swappable commercial electric vehicles (EVs) and creating 14 modular battery swapping stations across the city. This major move towards sustainable transportation follows a smaller pilot in Kyoto last year and will feature MFTBC's eCanter light-duty truck and Mitsubishi Motors' Minicab EV, targeting commercial delivery fleets. Yamato Transport will be the first major customer, focusing on last-mile delivery applications. Ample, a US-based battery swapping company, will provide the technology for the EV platforms and will be responsible for installing and operating the swapping stations. The Tokyo Metropolitan Environment Public Corporation is backing the project through its "Technology Development Support Project for Promoting New Energy", aligning with Japan's climate goals. Japan aims to reduce greenhouse gas emissions by 46% from 2013 levels by 2030 and achieve carbon neutrality by 2050. With the transportation sector responsible for nearly 19% of the country's CO₂ emissions in 2022, commercial fleet electrification is a strategic priority for Japan's decarbonisation efforts. The consortium in Tokyo is targeting battery swapping times of just five minutes, offering a fully automated service where drivers do not need to exit their vehicles. Ample's compact and rapidly deployable stations are a practical solution for high-utilisation fleets in dense urban areas like Tokyo. Future expansions of this initiative may include grid services, such as renewable energy storage, to further reduce greenhouse gas emissions. This initiative builds on previous collaborations, with Yamato Transport pioneering commercial EV battery swapping since 2022 and a successful pilot involving commercial delivery and battery swapping taxis in Kyoto in 2024. "Mitsubishi plans battery swapping tech for electric CVs in Tokyo" was originally created and published by Just Auto, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store